Anti-lps.html

Anti-LPS

Lipopolysaccharide (LPS), or endotoxin, is the major mediator of septic shock, a serious complication of Gram-negative bacterial infections in humans. Molecules that bind LPS and neutralize its biological effects or enhance its clearance could have important clinical applications. Limulus anti-LPS factor (LALF) binds LPS

Horseshoe crabs (Limulus polyphemus and Tachypleus tridentatus) are  ancient arachnids that possess a primitive circulatory system, the hemolymph, containing only one kind of cell, the hemocyte. Exposure of hemocytes to bacterial endotoxins [lipopolysaccharide (LPS)] results in the activation of an intracellular coagulation cascade (Iwanaga et al., 1986), a defense against microbial invasion. The system consists of several proteins, including one that may inhibit the cascade, called anti-LPS factor(Morita et al., 1985). Limulus anti-LPS factor (LALF) is a small (101 amino acids), basic protein (Aketagawa et al., 1986; Muta et al., 1987), which binds and neutralizes LPS (Wainwright et al., 1990) and has a strong anti-bacterial effect on the growth of Gram-negative R-type bacteria (Morita et al., 1985)(22). Our interest in determining the crystal structure of LALF arose from its potential in designing molecules that would have therapeutic properties in humans. It has been proposed that LALF has sequence similarity with ct-lactalbumin, a protein that binds LPS in vitro (Aketagawa et al., 1986).

     LALF recognizes the lipid A portion of individual soluble LPS molecules (Warren et al., 1992), which are obtained below the critical micellar concentration. The simplest molecules that bind lipid A with high affinity are the polymyxin family of antibiotics; these are positively charged amphipathic cyclic oligopeptides linked to a single fatty acid (Morrison and Jacobs, 1976).

Freeze fracture electron micrographs of LPS. Alone (A), in the presence of LALF supernatant (B) and precipitation (C).( Mechanism of interaction of optimized Limulus-derived cyclic peptides with endotoxins: thermodynamic, biophysical and microbiological analysis
Jorg ANDR¨A, Jorg HOWE, Patrick GARIDEL, Manfred R OSSLE, Walter RICHTER§, Jos´e LEIVA-LE ´ON_, Ignacio

    Endotoxin-neutralizing protein protects against Endotoxin-Induced Endothelial Barrier Dysfunction. Endotoxin-neutralizing protein, a recombinant peptide that is derived from Limulus antilipopolysaccharide factor and targets lipid A, could block the effects of lipopolysaccharide on protein tyrosine phosphorylation, actin organization, and movement of 14C-bovine serum albumin across bovine pulmonary artery endothelial cell monolayers. endotoxin-neutralizing protein crossprotected against lipopolysaccharide derived from diverse gram-negative bacteria. LALF is a 11.8-kDa protein isolated from the amebocyte, the single blood cell type found in the horseshoe crab (13). The amebocyte-derived LALF as well as its recombinant form, endotoxin-neutralizing protein (ENP), each binds to and neutralizes LPS (13, 18). The LPS-binding site is 32 to 50 amino acids in length and forms an amphipathic loop which binds to the lipid A portion of LPS (11, 15, 18). We therefore studied whether a molecule such as ENP, which binds to lipid A and has been shown to confer protection against the deleterious effect of LPS in vivo, could block one or more of the sequential LPS-induced events leading to increased EC monolayer permeability. In this work, we have studied whether ENP protects against LPS-induced protein tyrosine phosphorylation, actin reorganization, and loss of endothelial barrier function. the importance of the amphipathic loop structure can be investigated by introducingappropriate disulfide bonds to create a cyclic conformation. However, previous investigations with cysteine- and non-cysteine- containing peptides derived from TALF, a protein highly homologous with LALF, showed little difference in LPS binding activity (23).

Considering that Limulus anti-lipopolysaccharide factor (LALF) reduces the growth of gram negative bacteria and terminates them; we determine that it can be used as a surface protector. In our Project, we plan to design LALF protein producing system in a specific bacteria that will not be harmed by this bactericide itself. To do this, we needed a bacteria type that has no lip-A structure which is bound by LALF. Thus, we decided to use Bacillus subtilis colonies which are the most prefered gram positive bacteria in iGEM. In conclusion, our “protector” bacteria affects on E. Coli mortally, therefore our remaining region is cleared from E.coli. As a future aspect, a special covering material, a biofilm for example, may be used as a cover sheet on surfaces that leads to protection of bacterias.

Binding of 1 mg/ml biotinylated LALF-14 to lipid A and different kinds of lipopolysaccharide adsorbed to a microtiter-plate (1.0 mg/ml).(From MorphoSys GmbH, 80807 Munich, Germany, the Institute of Medical Microbiology and Hygiene, Technical University of Munich, 81675 Munich, Germany, and the Institute of Medical Immunology, Humboldt University of Berlin, 10098 Berlin, Germany. High Affinity Endotoxin-binding and Neutralizing Peptides Based on the Crystal Structure of Recombinant Limulus
Anti-lipopolysaccharide Factor).The important indication of this figure for our project is E.coli’s OD on 450 nm.

REFERENCES

1. Alpert G, Baldwin G, Thompson C, Wainwright N, Novitsky T J, Gillis  , Parsonnet J, Fleisher G R, Siber G R. Limulus antilipopolysaccharide
factor protects rabbits from meningococcal endotoxin shock. J Infect Dis. 1992;165:494–500. [PubMed]
2. Bannerman D D, Goldblum S E. Endotoxin induces endothelial barrier dysfunction through protein tyrosine phosphorylation. Am J Physiol.
1997;273:L217–L226. [PubMed]
3. Battafaraono R J, Dahlberg P S, Ratz C A, Johnston J W, Gray B H, Haseman J R, Mayo K H, Dunn D L. Peptide derivatives of three distinct
lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro. Surgery.
1995;118:318–324. [PubMed]
4. Cooperstock M S. Inactivation of endotoxin by polymyxin B. Antimicrob Agents Chemother. 1974;6:422–425. [PMC free article] [PubMed]
5. Evans T J, Carpenter A, Moyes D, Martin R, Cohen J. Protective effects of a recombinant amino-terminal fragment of human
bactericidal/permeability-increasing protein in an animal model of gram negative sepsis. J Infect Dis. 1995;171:153–160. [PubMed]
6. Fletcher M A, Mckena T M, Quance J L, Wainwright N R, Williams T J. Lipopolysaccharide detoxification by endotoxin neutralizing protein. J
Surg Res. 1993;55:147–154. [PubMed]
7. Frey E A, Miller D S, Jahr T G, Sundan A, Bazil V, Espevik T, Finlay B B, Wright S D. Soluble CD14 participates in the response of cells to
lipopolysaccharide. J Exp Med. 1992;176:1665–1671. [PMC free article] [PubMed]
8. Goldblum S E, Brann T W, Ding X, Pugin J, Tobias P S. Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro. J Clin Invest. 1994;93:692–702. [PMC free article] [PubMed]
9. Goldblum S E, Ding X, Brann T W, Campbell-Washington J. Bacterial lipopolysaccharide induces actin reorganization, intercellular gap
formation, and endothelial barrier dysfunction in pulmonary vascular endothelial cells: concurrent F-actin depolymerization and new actin
synthesis. J Cell Physiol. 1993;157:13–23. [PubMed]
10. Hirata M, Zhong J, Wright S C, Larrick J W. Structure and functions of endotoxin-binding peptides derived from CAP18. Prog Clin Biol Res.
1995;392:317–326. [PubMed]
11. Hoess A, Watson S, Siber G R, Liddington R. Crystal structure of endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS
factor, at 1.5 A resolution. EMBO J. 1993;12:3351–3356. [PMC free article] [PubMed]
12. Levine D M, Parker T S, Donelly T M, Walsh A, Rubin A L. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl
Acad Sci USA. 1993;90:12040–12044. [PMC free article] [PubMed]
13. Morita T, Ohtsubo S, Nakamura T, Tanaka S, Iwanaga S, Ohashi K, Niwa M. Isolation and biological activities of limulus anticoagulant
(anti-LPS factor) which interacts with lipopolysaccharide (LPS) J Biochem (Tokyo) 1985;97:1611–1620. [PubMed]
14. Morrison D C, Jacobs D M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry.
1976;13:813–818. [PubMed]
15. Muta T, Miyata T, Tokunaga F, Nakamura T, Iwanaga S. Primary structure of anti-lipopolysaccharide factor from American horseshoe crab,
Limulus polyphemus. J Biochem (Tokyo) 1987;101:1321–1330. [PubMed]
16. Netea M G, Demacker P N M, Kullberg B J, Boerman O C, Verschueren I, Stalenhoef A F H, van der Meer J W M. Low-density lipoprotein
receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J Clin Invest. 1996;97:1366–1372.
[PMC free article] [PubMed]
17. Ulevitch R J, Tobias P S. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol. 1994;6:125–130.
[PubMed]
18. Wainwright N R, Miller R J, Paus E, Novitsky T J, Fletcher M A, McKenna T M, Williams T. Endotoxin binding and neutralizing activity by a
protein from Limulus polyphemus. In: Levin J, Alving C R, Munford R S, Stutz P L, editors. Cellular and molecular aspects of endotoxin
reactions. New York, N.Y: Elsevier Science Publishers; 1990. pp. 315–325.
19. Warren H S, Novitsky T J, Bucklin A, Kania S A, Siber G R. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other
gram-negative bacteria. Infect Immun. 1987;55:1668–1673. [PMC free article] [PubMed]
20. Weinstein S L, June C H, DeFranco A L. Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated
by CD14. J Immunol. 1993;151:3829–3838. [PubMed]
21. A. Hoess, S. Watson, G.R.Siber and R.Liddington.Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution.
22. Lihua Wu, Chao-Ming Tsai and Carl E. Frasch.A method purification of bacterial R-type LPS.
23. Kloczewiak, M., Black, K. M., Loiselle, P., Cavaillon, J. M., Wainwright, N., and Warren, H. S. (1994) J. Infect. Dis. 170, 1490–1497